Industry News
Drawbridge wins patents for anaesthesia candidate
Drawbridge Pharmaceuticals has picked up patents in six countries for Phaxan, its anaesthesia drug candidate that entered the phase IC trial stage this month. [ + ]
Viralytics to raise up to $27m for cancer trials
Viralytics (ASX:VLA) has launched a capital raising to secure funds for clinical trials of cancer treatment candidate Cavatak in melanoma and other solid tumours. [ + ]
Qiagen submits C. difficile assay to FDA
Qiagen plans to roll out a portfolio of assays for the QIAsymphony platform to aid in the diagnosis of healthcare-associated infections (HAIs). The company's first new test, the artus C. difficile QS-RGQ MDx Kit, has been submitted to the US Food and Drug Administration (FDA). [ + ]
Burnet Institute to roll out cheap point-of-care HIV test
Burnet Institute has received US$1.6 million from UNITAID to begin evaluation studies of HIV test VISITECT CD4 in India and South Africa. The point-of-care test uses a small amount of blood from a finger prick to determine when an HIV-positive patient should start lifesaving treatment. Results of the test are available after 40 min at a cost of approximately $5. [ + ]
Spinning cloth disc reactor accelerates enzyme reactions
Researchers from the University of Bath have developed a new enzymatic process intensification technology - the 'spinning cloth disc reactor' (SCDR) - which is one of only a few technologies available for accelerating the rate of an enzyme reaction. [ + ]
Nanoparticles provide a new way to treat heart attack
Researchers are recruiting nanobiology to change the way heart attacks are treated. [ + ]
Modelling ovarian cancer
Scientists at Queensland University of Technology (QUT), funded by Cancer Council Queensland, are conducting research into the deadliest form of ovarian cancer. [ + ]
Calzada scores licence deal for AOD9604
Calzada (ASX:CZD) subsidiary Metabolic has secured the first of what it hopes will be a number of licensing agreements with Australian compounding pharmacies for its peptide drug AOD9604. [ + ]
IDT Australia weighing acquiring HRT product
IDT Australia (ASX:IDT) is evaluating acquiring Perrigo's US ANDA filing for a synthetic oestrogen product, as it seeks to expand its specialty generic drug portfolio. [ + ]
Annual CEO industry survey to check the 'pulse' of the Australian industry
AusBiotech calls on industry leaders (CEOs and MDs) to respond to the annual Biotechnology Industry Position Survey 2014 in order to contribute to the annual snapshot and build the advocacy platform for the year to come. [ + ]
Transforming catheter placement
A new tool that guides catheter placement is being taken up by Australian hospitals. [ + ]
Thousand-dollar genome a reality
The dream of sequencing an entire human genome for $1000 has become a reality. [ + ]
Academy of Science awards scientific excellence
The 2014 winners of the Australian Academy of Science's prestigious annual awards for scientific excellence have been announced. [ + ]
Cochlear facing $150m penalty from patent case
A US jury has found Cochlear (ASX:COH) liable of patent infringement and awarded damages of US$131.2m, but the company has vowed to appeal. [ + ]
iSonea products recognised at CES
iSonea (ASX:ISN) has picked up a Tech Podcast Network award for its asthma symptom monitoring tools AirSonea and AsthmaSense Prime. [ + ]